These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
380 related articles for article (PubMed ID: 34365463)
1. Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression. Xu P; Xiong W; Lin Y; Fan L; Pan H; Li Y Cell Death Dis; 2021 Aug; 12(8):779. PubMed ID: 34365463 [TBL] [Abstract][Full Text] [Related]
2. Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1. Liu J; Yang Y; Wang H; Wang B; Zhao K; Jiang W; Bai W; Liu J; Yin J Breast Cancer Res Treat; 2018 Sep; 171(2):345-357. PubMed ID: 29845474 [TBL] [Abstract][Full Text] [Related]
3. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer. Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606 [TBL] [Abstract][Full Text] [Related]
4. JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer. Chen M; Pockaj B; Andreozzi M; Barrett MT; Krishna S; Eaton S; Niu R; Anderson KS Clin Breast Cancer; 2018 Oct; 18(5):e1205-e1215. PubMed ID: 29933930 [TBL] [Abstract][Full Text] [Related]
5. UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced Wu B; Song M; Dong Q; Xiang G; Li J; Ma X; Wei F Theranostics; 2022; 12(11):5086-5102. PubMed ID: 35836797 [No Abstract] [Full Text] [Related]
6. ALG3 predicts poor prognosis and increases resistance to anti-PD-1 therapy through modulating PD-L1 N-link glycosylation in TNBC. Luo B; Liu X; Zhang Q; Liang G; Zhuang Y Int Immunopharmacol; 2024 Oct; 140():112875. PubMed ID: 39116492 [TBL] [Abstract][Full Text] [Related]
7. IFNγ-induced PD-L1 expression in ovarian cancer cells is regulated by JAK1, STAT1 and IRF1 signaling. Padmanabhan S; Gaire B; Zou Y; Uddin MM; Vancurova I Cell Signal; 2022 Sep; 97():110400. PubMed ID: 35820543 [TBL] [Abstract][Full Text] [Related]
8. NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer. Qin G; Wang X; Ye S; Li Y; Chen M; Wang S; Qin T; Zhang C; Li Y; Long Q; Hu H; Shi D; Li J; Zhang K; Zhai Q; Tang Y; Kang T; Lan P; Xie F; Lu J; Deng W Nat Commun; 2020 Apr; 11(1):1669. PubMed ID: 32245950 [TBL] [Abstract][Full Text] [Related]
9. HDAC is indispensable for IFN-γ-induced B7-H1 expression in gastric cancer. Deng R; Zhang P; Liu W; Zeng X; Ma X; Shi L; Wang T; Yin Y; Chang W; Zhang P; Wang G; Tao K Clin Epigenetics; 2018 Dec; 10(1):153. PubMed ID: 30537988 [TBL] [Abstract][Full Text] [Related]
10. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells. Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303 [TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells. Sasidharan Nair V; Toor SM; Ali BR; Elkord E Expert Opin Ther Targets; 2018 Jun; 22(6):547-557. PubMed ID: 29702007 [TBL] [Abstract][Full Text] [Related]
12. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells. Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543 [TBL] [Abstract][Full Text] [Related]
13. APLNR inhibited nasopharyngeal carcinoma growth and immune escape by downregulating PD-L1. Liu Y; Li N; Guo Y; Zhou Q; Yang Y; Lu J; Tian Z; Zhou J; Yan S; Li X; Shi L; Jiang S; Ge J; Feng R; Huang D; Zeng Z; Fan S; Xiong W; Li G; Zhang W Int Immunopharmacol; 2024 Aug; 137():112523. PubMed ID: 38909500 [TBL] [Abstract][Full Text] [Related]
14. Triptolide suppresses oral cancer cell PD-L1 expression in the interferon-γ-modulated microenvironment in vitro, in vivo, and in clinical patients. Kuo CS; Yang CY; Lin CK; Lin GJ; Sytwu HK; Chen YW Biomed Pharmacother; 2021 Jan; 133():111057. PubMed ID: 33378962 [TBL] [Abstract][Full Text] [Related]
15. MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer. Maeda T; Hiraki M; Jin C; Rajabi H; Tagde A; Alam M; Bouillez A; Hu X; Suzuki Y; Miyo M; Hata T; Hinohara K; Kufe D Cancer Res; 2018 Jan; 78(1):205-215. PubMed ID: 29263152 [TBL] [Abstract][Full Text] [Related]
16. STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression. Song YM; Qian XL; Xia XQ; Li YQ; Sun YY; Jia YM; Wang J; Xue HQ; Gao GS; Wang XZ; Zhang XM; Guo XJ Breast Cancer Res Treat; 2022 Nov; 196(1):45-56. PubMed ID: 36056297 [TBL] [Abstract][Full Text] [Related]
17. Breast cancer cells promote CD169 Jing W; Guo X; Wang G; Bi Y; Han L; Zhu Q; Qiu C; Tanaka M; Zhao Y Int Immunopharmacol; 2020 Jan; 78():106012. PubMed ID: 31865052 [TBL] [Abstract][Full Text] [Related]
18. [Plasma exosomal miR-335-5p serves as a diagnostic indicator and inhibits immune escape in triple-negative breast cancer]. Chen T; Dong Y; Wu X Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Apr; 38(4):347-356. PubMed ID: 35583065 [TBL] [Abstract][Full Text] [Related]
19. Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cells. Coombs MRP; Harrison ME; Hoskin DW Cancer Lett; 2016 Oct; 380(2):424-433. PubMed ID: 27378243 [TBL] [Abstract][Full Text] [Related]
20. Ginsenoside Rh4 inhibits breast cancer growth through targeting histone deacetylase 2 to regulate immune microenvironment and apoptosis. Dong F; Qu L; Duan Z; He Y; Ma X; Fan D Bioorg Chem; 2023 Jun; 135():106537. PubMed ID: 37043883 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]